DPX-Survivac and Checkpoint Inhibitor in DLBCL

Conditions:   Adult Diffuse Large Cell Lymphoma;   Recurrent;   Adult Refractory Diffuse Large B-Cell Lymphoma Interventions:   Biological: DPX-Survivac;   Biological: Pembrolizumab;   Drug: Cyclophosphamide 50mg Sponsors:   Sunnybrook Health Sciences Centre;   ImmunoVaccine Technologies, Inc.;   Merck Sharp & Dohme Corp. Not yet recruiting

Source: ClinicalTrials.gov - November 21, 2017 Category: Research Source Type: clinical trials